Plain-English translation of NCT06627244 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether using —a new immunotherapy drug—together with a special radiation treatment called radioembolization can help people with uveal melanoma (a rare eye cancer) that has spread to the liver. The radiation treatment delivers powerful beams directly into the liver tumors, and then the immunotherapy helps the body's immune system fight any remaining cancer cells. Researchers want to see how well this combination works and what side effects patients experience.
Uveal melanoma that spreads to the liver is very difficult to treat, and most people don't survive long after diagnosis. This trial is exploring whether this medication, combined with a targeted radiation technique, might offer a better option than existing treatments.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will first receive the radiation treatment (radioembolization) to your liver, followed by a 2–4 week recovery period. Then you will receive weekly injections of the medication for up to 24 months, with each treatment cycle lasting 28 days. Your participation will last about 3 years total, including follow-up visits to monitor your health, blood tests, and imaging scans to see how well the treatment is working.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
University of Miami
Collaborators
Immunocore Ltd
Enrollment target
~30 participants
Started
February 2025
Primary completion
February 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lynn Feun, MD
University of Miami
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.